Misplaced Pages

This is an old revision of this page, as edited by Dekimasu (talk | contribs) at 13:31, 5 February 2020 (cleanup). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

2019-nCoV acute respiratory disease is a viral respiratory disease of zoonotic origin caused by the 2019 novel coronavirus (2019-nCoV), first seen during the 2019–20 Wuhan coronavirus outbreak. The name "2019-nCoV acute respiratory disease" is a temporary designation from the World Health Organization (WHO).

No specific treatment verified by medical research standards (in the sense of systematic reviews of peer reviewed randomized controlled clinical trials) is available as of February 2020, so treatment is focused on alleviation of symptoms, which may include fever, dry cough, and shortness of breath.

In its advanced stages, infection by 2019-nCoV can cause pneumonia and kidney failure.

Treatment research

Template:2019-20 Wuhan coronavirus data/Treatments given

Multiple lines of exploratory research into potential treatments for the disease were initiated in January 2020. The Chinese Center for Disease Control and Prevention started testing existing pneumonia treatments for efficacy in treating coronavirus-related pneumonia in late January. Investigations into the effectiveness of existing antivirals, including protease inhibitors like indinavir, saquinavir and lopinavir/ritonavir also started in late January. Examination of the RNA polymerase inhibitor remdesivir, interferon beta, and previously identified monoclonal antibodies (mAbs) as possible treatments also started around the same period. Researchers from the Norwegian University of Science and Technology (NTNU) have created a database with 120 safe-in-man broad-spectrum antiviral agents and identified 31 drug candidates for treatment of 2019-nCoV.

In late January 2020, Chinese medical researchers expressed an intent to start clinical testing on remdesivir, chloroquine, and lopinavir/ritonavir, all of which seemed to have "fairly good inhibitory effects" on 2019-nCoV at the cellular level in exploratory research. On 2 February 2020, doctors in Thailand claimed to have treated a patient successfully with a combination of lopinavir/ritonavir and the influenza drug oseltamivir.

References

1. Novel Coronavirus (2019-nCoV): Situation Report - 10 (30 January 2020) (PDF) (Report). World Health Organization (WHO). 30 January 2020. Archived from the original (PDF) on 31 January 2020. Retrieved 30 January 2020. {{cite report}}: Unknown parameter |lay-url= ignored (help)
2. Georgiadis, Philip. "WHO plays down reports of virus treatment". Financial Times. Retrieved 5 February 2020.
3. "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 3 February 2020.
4. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020 Jan 14;91:264–266. doi:10.1016/j.ijid.2020.01.009. PMID 31953166.
5. "Q&A on coronaviruses". World Health Organization (WHO). Archived from the original on 20 January 2020. Retrieved 27 January 2020.
6. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 28 Jan 2020. doi:10.5582/bst.2020.01020
7. "China CDC developing novel coronavirus vaccine". Xinhua. 26 January 2020. Archived from the original on 26 January 2020. Retrieved 28 January 2020.
8. "WHO says new China coronavirus could spread, warns hospitals worldwide". Reuters. 14 January 2020. Archived from the original on 20 January 2020. Retrieved 21 January 2020.
9. "China Testing HIV Drug as Treatment for New Coronavirus, AbbVie Says". The New York Times. 26 January 2020. Archived from the original on 1 February 2020. Retrieved 2 February 2020.
10. "Flu and HIV Drugs Show Efficacy Against Coronavirus | The Scientist Magazine®". www.the-scientist.com.
11. "Anti-novel coronavirus drug under clinical trial: official". Xinhuanet. Archived from the original on 3 February 2020. Retrieved 3 February 2020.
12. Xu, Zhijian; Peng, Cheng; Shi, Yulong; Zhu, Zhengdan; Mu, Kaijie; Wang, Xiaoyu; Zhu, Weiliang (28 January 2020). "Nelfinavir was predicted to be a potential inhibitor of 2019 nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation". bioRxiv: 2020.01.27.921627. doi:10.1101/2020.01.27.921627 – via www.biorxiv.org.
13. ^ Paules, Catharine I.; Marston, Hilary D.; Fauci, Anthony S. (23 January 2020). "Coronavirus Infections—More Than Just the Common Cold". JAMA. doi:10.1001/jama.2020.0757. PMID 31971553.
14. "Coronavirus: Vir Biotechnology and Novavax announce vaccine plans-GB". Retrieved 26 January 2020.
15. Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjoras M, Telling K, Lutsar I, Dumpis U, Irie Y, Tenson T. "Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents". Preprints. 0 (0): null. doi:10.20944/preprints201910.0144.v4. {{cite journal}}: Cite has empty unknown parameter: |1= (help)CS1 maint: unflagged free DOI (link)
16. Zhao, Yuning (2020-01-30). "Three drugs fairly effective on novel coronavirus at cellular level". China News Service. Archived from the original on 2020-01-29. Retrieved 2020-02-01. {{cite web}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
17. "Coronavirus: Thailand has apparent treatment success with antiviral drug cocktail". South China Morning Post. 2 February 2020. Archived from the original on 2 February 2020. Retrieved 3 February 2020.
18. "Cocktail of flu, HIV drugs appears to help fight coronavirus: Thai doctors". Reuters. 2020-02-03. Retrieved 2020-02-05.

• Medicine
• Viruses